We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Authors
Ammann, Eric M.; Shanafelt, Tait D.; Larson, Melissa C.; Wright, Kara B.; McDowell, Bradley D.; Link, Brian K.; Chrischilles, Elizabeth A.
- Abstract
<bold>Background: </bold>Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). However, there is disagreement over how widely these therapies should be used in place of standard chemo-immunotherapy (CIT). We investigated whether stratification on the length of the interval between first-line (T1) and second-line (T2) treatments could identify a subgroup of older patients with relapsed CLL/SLL with an expectation of normal overall survival, and for whom CIT could be an acceptable treatment choice.<bold>Patients and Methods: </bold>Patients with relapsed CLL/SLL who received T2 were identified from the SEER-Medicare Linked Database. Five-year relative survival (RS5; ie, the ratio of observed survival to expected survival based on population life tables) was assessed after stratifying patients on the interval between T1 and T2. We then validated our findings in the Mayo Clinic CLL Database.<bold>Results: </bold>Among 1974 SEER-Medicare patients (median age = 77 years) who received T2 for relapsed CLL/SLL, longer time-to-retreatment was associated with a modestly improved prognosis (P = .01). However, even among those retreated ≥ 3 years after T1, survival was poor compared with the general population (RS5 = 0.50 or lower in SEER-Medicare). Similar patterns were observed in the younger Mayo validation cohort, although prognosis was better overall among the Mayo patients, and patients with favorable fluorescence in situ hybridization retreated ≥ 3 years after T1 had close to normal expected survival (RS5 = 0.87).<bold>Conclusion: </bold>Further research is needed to quantify the degree to which targeted therapies provide meaningful improvements over CIT in long-term outcomes for older patients with relapsed CLL/SLL.
- Subjects
UNITED States; CHRONIC lymphocytic leukemia treatment; CANCER relapse; DRUG therapy; CHRONIC lymphocytic leukemia; REPORTING of diseases; IMMUNOTHERAPY; LONGITUDINAL method; MEDICARE; RESEARCH funding; SURVIVAL analysis (Biometry); TREATMENT effectiveness
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2017, Vol 17, Issue 12, pe11
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2017.07.004